about
Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700smiR-193a-3p is a potential tumor suppressor in malignant pleural mesotheliomaPosttranscriptional Regulation Controls Calretinin Expression in Malignant Pleural Mesothelioma.Haemolysis during sample preparation alters microRNA content of plasma.Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM).MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma.Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma.MicroRNA gene expression signatures in long-surviving malignant pleural mesothelioma patients.An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.Circulating microRNAs: Association with disease and potential use as biomarkers.Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma.Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.Cell-free microRNAs: potential biomarkers in need of standardized reporting.ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma.Does miR-1 play a role in malignant pleural mesothelioma development and progression?A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma.Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase/MMP1 signal.A data-driven, knowledge-based approach to biomarker discovery: application to circulating microRNA markers of colorectal cancer prognosis.When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?Molecular Research in Chronic Thromboembolic Pulmonary HypertensionTranscriptional suppression of the miR-15/16 family by c-Myc in malignant pleural mesotheliomamiR-625-3p and lncRNA GAS5 in Liquid Biopsies for Predicting the Outcome of Malignant Pleural Mesothelioma Patients Treated with Neo-Adjuvant Chemotherapy and SurgeryP35. Fibroblast growth factor signals and their connection to micrornas in malignant pleural mesothelioma
P50
Q28396964-D858DC34-66D7-4B23-B06F-F3773092A63EQ28397829-C5D141A0-841F-4D69-A499-F24FF21F54B7Q33734673-9A86C41D-270D-4192-9440-21D88D1A9A2FQ34016595-CCC54A12-AF25-4F5E-9364-D339F788DEA2Q34970431-C7790FC9-EB6C-421C-8FBE-1AD89CC9DC65Q35511541-53EA3BB1-30E7-4A2C-ACC7-740EBC9ED52BQ36035319-E9881FF0-4C11-4BE6-99FD-AD454818AE3CQ36081391-1B19CF55-AF65-40F8-937A-4736F3C4ADF7Q36662001-99F98107-8E3E-4B2B-9B34-4A37AD116E58Q37049227-DF523B2E-EE13-4517-A10C-91D5BFACB367Q37507415-C9E489E8-DAFA-4AE2-8757-B38974C5244AQ37818867-0C9AB8DC-57A1-4F36-807C-156DA1B80689Q38718563-D9CCF18D-BE3E-4D37-BE57-2B99D3E087F6Q38893024-EEC9FDF7-392E-40B4-839A-F32F7E2E1F10Q39073648-F7F3A331-7006-4991-AF6B-8EFE7F880256Q39946127-5F1F4185-F889-44AB-8010-976EDF4CF37AQ43823606-A9289094-29BC-482B-BE53-951C9FFF84C5Q44028742-E82DDCC9-D8F4-43B8-A144-25B3D757A5E6Q44660315-7F234E60-B02F-49D3-AC94-60B21AEE3C29Q47162061-1883158E-3F1E-48B0-883B-77B3044B532CQ47428855-7D478771-2ABA-4678-A5B8-F5DB31921281Q50041890-7A880EC4-4ECE-40B0-9AB5-404724D6D314Q51509080-EA1363C6-1B70-4173-84E5-E96D8823C227Q52596095-06A54495-D0EA-457B-8C6D-16EBBBDC45B5Q55166178-840EFB71-86FC-46CA-9689-8F07A81AF5BFQ64100362-13E46859-E12A-4F24-B5D0-8489972C3CA3Q64276905-33E20152-2CAE-4FCB-901B-78F90DE184BFQ91756679-EA3B41D5-463B-4193-8A5A-895AB5BCFDB5Q92856089-D9E9A67F-3D5D-4C34-8319-19D42430D8A1Q94371135-8163EDD3-A6BD-451D-9ED4-C81DADC15CD6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michaela B Kirschner
@nl
Michaela B Kirschner
@sl
Michaela B. Kirschner
@en
Michaela B. Kirschner
@es
type
label
Michaela B Kirschner
@nl
Michaela B Kirschner
@sl
Michaela B. Kirschner
@en
Michaela B. Kirschner
@es
prefLabel
Michaela B Kirschner
@nl
Michaela B Kirschner
@sl
Michaela B. Kirschner
@en
Michaela B. Kirschner
@es
P1053
D-2214-2015
P106
P1153
36657219900
P1960
7MRS52IAAAAJ
P2038
Michaela_Kirschner
P21
P2798
P31
P3829
P3835
michaela-b-kirschner
P496
0000-0001-7444-9829